Furthermore, participants assigned to tirzepatide had a slower mean rate of decline in estimated glomerular filtration rate over the study period: 1.4 0.2 ml/min/1.73 m 2 body mass per year with tirzepatide compared with 3.6 0.2 ml/min/1.73 m 2 body mass per year with insulin glargine, for a between-group difference of 2.2 ml/min/1.73 m 2 body mass per year [95% CI 1.62.8 ml/min/1.73 m 2 body mass per year] [95]
Case Study Outpatient Office
GLP-1 agonists appear to flatten these surges, reducing the rewarding hit that drives drinking, smoking, overeating, or drug use
Convenient, affordable, and available over the counter
Individual nausea responses depend on dose, genetics, and eating patterns rather than formulation type
After one year, there was no evidence of any benefit on a wide range of cognitive and physical outcomes